Adaptive Biotechnologies (ADPT) Cost of Revenue: 2018-2025
Historic Cost of Revenue for Adaptive Biotechnologies (ADPT) over the last 8 years, with Sep 2025 value amounting to $23.5 million.
- Adaptive Biotechnologies' Cost of Revenue rose 14.20% to $23.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.7 million, marking a year-over-year increase of 7.73%. This contributed to the annual value of $84.8 million for FY2024, which is 4.31% down from last year.
- According to the latest figures from Q3 2025, Adaptive Biotechnologies' Cost of Revenue is $23.5 million, which was down 0.44% from $23.6 million recorded in Q2 2025.
- Adaptive Biotechnologies' Cost of Revenue's 5-year high stood at $26.7 million during Q4 2021, with a 5-year trough of $20.3 million in Q2 2024.
- In the last 3 years, Adaptive Biotechnologies' Cost of Revenue had a median value of $22.3 million in 2023 and averaged $22.1 million.
- Per our database at Business Quant, Adaptive Biotechnologies' Cost of Revenue skyrocketed by 72.37% in 2021 and then decreased by 14.90% in 2024.
- Quarterly analysis of 5 years shows Adaptive Biotechnologies' Cost of Revenue stood at $26.7 million in 2021, then decreased by 11.16% to $23.7 million in 2022, then dropped by 7.63% to $21.9 million in 2023, then dropped by 1.51% to $21.6 million in 2024, then increased by 14.20% to $23.5 million in 2025.
- Its Cost of Revenue stands at $23.5 million for Q3 2025, versus $23.6 million for Q2 2025 and $23.0 million for Q1 2025.